What’s new with GBI Research's Premium Reports under the Chemicals Industry
22 Nov 2011 • by Natalie Aster
Market Publishers Ltd informs that new GBI Research's Chemicals Industry report has been added to its catalogue:
The global demand for benzene has been growing slowly over the last decade. Global demand in 2000 was 27,337,573 tons. Global benzene demand increased to 29,109,204 in 2010. Much of the increase in demand for benzene came from the Asia-Pacific region and the same trend is expected to continue in the future. Asia-Pacific is expected to account for 61.6% of the global benzene demand in 2020 which is expected to grow to reach to 42,292,167 tons in 2020.
Ethylbenzene/styrene monomer and cumene/phenol have demand shares of 52.6% and 18.3% of global benzene market respectively, leading end-use segments for benzene in 2010. Together they constitute more than 70% of global benzene demand. Other uses such as cyclohexane, nitrobenzene and LAB collectively consumed less than 15% of the global benzene demand in 2010. With further evolution of the global market and more utilization of rubber products, coatings and adhesives the dominance of ethylbenzene and cumene is expected to strengthen, increasing their consumption share in the overall benzene demand.
The API market revenues in the Americas are expected to grow at a compound annual growth rate (CAGR) of 4.7% from 2010 to 2015. The US has been the world’s largest pharmaceutical market historically, it has a dominating share of the Americas’ API market revenues. As the North American pharmaceutical market recovers from the impacts of economic downturn, API market revenues are expected to witness steady growth. The faster growing markets of South and Central America will provide a greater contribution to the overall growth of the API market in the Americas. Brazil in particular is witnessing very strong growth in pharmaceuticals and API market revenues and is expected to overtake Mexico in the coming years.
The American pharmaceutical and API market has been historically dominated by the branded sector. However, the growth pattern is rapidly changing. As a consequence of the impact of the global economic slowdown on some of the major American economies, the expenditure on research and innovation is controlled to some extent. Due to this, the growth of the branded sector of the API market has been impacted. On the other hand, the generic API sector is witnessing strong growth. This is mostly because of the patent expiries of some of the major branded drugs as well as healthcare cost containment measures. Generic sector APIs are expected to hold an increased share of the overall API market in the Americas by 2015.
Report Price: $3500 (Single User License)
More new market research reports by GBI Research can be found at publisher page.
To order the report or ask for sample pages contact [email protected]